Oncology Medical News about ovarian cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
Gynecologic Oncology, 06/30/09

Smith HO et al. - Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.

<< Previous
Combined weekly carboplatin and paclitaxel as primary treatment...

Next >>
Topotecan versus treosulfan, an alkylating agent, in patients...

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09 Relevance Score: 72%

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09 Relevance Score: 70%

Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09 Relevance Score: 70%

New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09 Relevance Score: 70%

New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09 Relevance Score: 70%